Global Cardiometabolic Disease Market Report and Forecast 2023-2031
Global Cardiometabolic Disease Market Outlook:
The global cardiometabolic disease market value was USD 111 billion in 2022, driven by the increasing prevalence of cardiometabolic diseases, including heart disease, stroke, obesity, diabetes, and metabolic syndrome across the globe. The market size is anticipated to grow at a CAGR of 3.8% during the forecast period of 2023-2031 to achieve a value of USD 155.9 billion by 2031.
Introduction
Cardiometabolic diseases encompass a group of medical conditions that involve both cardiovascular and metabolic disorders. These conditions include heart disease, stroke, obesity, diabetes, and metabolic syndrome. They pose a significant global health burden, contributing to morbidity, mortality, and healthcare costs.
The prevalence of cardiometabolic diseases is on the rise worldwide, largely driven by factors such as sedentary lifestyles, unhealthy diets, tobacco use, and an aging population. These diseases are closely interrelated, with shared risk factors and underlying mechanisms. For instance, obesity and insulin resistance are key contributors to the development of both diabetes and cardiovascular disease.
Key Trends in the Cardiometabolic Disease Market
Some key trends involved in the cardiometabolic disease market are as follows:
One key trend in the field of cardiometabolic diseases is the growing emphasis on prevention and early intervention. Recognizing the importance of addressing risk factors and adopting a proactive approach, healthcare systems and public health initiatives are increasingly focusing on promoting healthy lifestyles, improving diet and physical activity, and implementing screening programs to detect and manage these conditions at an early stage.
Another trend is the development of innovative therapeutics and treatment strategies. Advancements in pharmacology and medical technology have led to the emergence of novel drugs, devices, and interventions that target specific aspects of cardiometabolic diseases. For example, there have been significant advancements in the field of anti-diabetic medications, lipid-lowering agents, and interventional cardiology procedures.
Cardiometabolic Disease Market Segmentations
Market by Type
Chronic/Congestive Heart Failure
Hypertension
Type 2 Diabetes
Obesity
Market by Treatment
ACE Inhibitors
Diuretics
Glucophage
Liposuction
Others
Market by Route of Administration
Oral
Intravenous
Others
Market Breakup by End User
Hospitals
Clinics
Other end-Users
Market Breakup by Region
North America
United States of America
Canada
Europe
United Kingdom
Germany
France
Italy
Others
Asia Pacific
China
Japan
India
ASEAN
Australia
Others
Latin America
Brazil
Argentina
Mexico
Others
Middle East and Africa
Saudi Arabia
United Arab Emirates
Nigeria
South Africa
Others
Cardiometabolic Disease Market Scenario
The global market for cardiometabolic diseases is experiencing significant growth and is expected to continue expanding in the coming years. Cardiometabolic diseases, including heart disease, stroke, obesity, diabetes, and metabolic syndrome, are major contributors to morbidity, mortality, and healthcare costs worldwide. The increasing prevalence of these conditions, driven by factors such as sedentary lifestyles, unhealthy diets, and an aging population, has created a substantial market demand for effective prevention, diagnosis, and treatment options.
The market is characterized by a wide range of pharmaceuticals, medical devices, and diagnostic tools specifically developed for the management of cardiometabolic diseases. Pharmaceutical interventions include anti-diabetic medications, lipid-lowering drugs, anti-hypertensive agents, and antiplatelet therapies, among others. Medical devices used in the treatment of these conditions include implantable cardioverter-defibrillators, pacemakers, stents, and continuous glucose monitoring systems. Diagnostic tools such as electrocardiography (ECG), echocardiography, and blood tests play a crucial role in the early detection and monitoring of cardiometabolic diseases.
Geographically, North America and Europe have traditionally been the largest markets for cardiometabolic diseases due to their well-established healthcare infrastructure and higher prevalence rates. However, emerging economies in Asia Pacific, Latin America, and the Middle East are witnessing rapid growth in this market due to the increasing incidence of cardiometabolic diseases and improving access to healthcare.
Cardiometabolic Disease Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
biocrates life sciences ag
Lilly
Alnylam Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc.
Cardax, Inc.
Novartis AG
Novo Nordisk A/S
Boehringer Ingelheim International GmbH
Kowa Company, Ltd
Allergan
AstraZeneca
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Cardiometabolic Disease Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Cardiometabolic Disease Epidemiology Analysis
- 5.1 Epidemiology Overview (2016-2031)
- 5.2 North America Cardiometabolic Disease Epidemiology (2016-2031)
- 5.3 Europe Cardiometabolic Disease Epidemiology (2016-2031)
- 5.4 Asia-Pacific Cardiometabolic Disease Epidemiology (2016-2031)
- 5.5 Latin America Cardiometabolic Disease Epidemiology (2016-2031)
- 5.6 Middle East & Africa Cardiometabolic Disease Epidemiology (2016-2031)
- 6 Cardiometabolic Disease Market Overview
- 6.1 Cardiometabolic Disease Market Historical Value (2016-2022)
- 6.2 Cardiometabolic Disease Market Forecast Value (2023-2031)
- 7 Cardiometabolic Disease Market Landscape
- 7.1 Cardiometabolic Disease: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Cardiometabolic Disease: Product Landscape
- 7.2.1 Analysis by Type
- 7.2.2 Analysis by Technology
- 8 Cardiometabolic Disease Market Dynamics
- 8.1 Market Drivers and Constraints
- 8.2 SWOT Analysis
- 8.3 Porter’s Five Forces Model
- 8.4 Key Demand Indicators
- 8.5 Key Price Indicators
- 8.6 Industry Events, Initiatives, and Trends
- 8.7 Value Chain Analysis
- 9 Cardiometabolic Disease Market Segmentation
- 9.1 Cardiometabolic Disease Market by Type
- 9.1.1 Market Overview
- 9.1.2 Chronic/Congestive Heart Failure
- 9.1.3 Hypertension
- 9.1.4 Type 2 Diabetes
- 9.1.5 Obesity
- 9.2 Cardiometabolic Disease Market by Treatment
- 9.2.1 ACE Inhibitors
- 9.2.2 Diuretics
- 9.2.3 Glucophage
- 9.2.4 Liposuction
- 9.2.5 Others
- 9.3 Cardiometabolic Disease Market by Route of Administration
- 9.3.1 Oral
- 9.3.2 Intravenous
- 9.3.3 Others
- 9.4 Cardiometabolic Disease Market by End User
- 9.4.1 Market Overview
- 9.4.2 Hospitals
- 9.4.3 Clinics
- 9.4.4 Other end-Users
- 9.5 Cardiometabolic Disease Market by Region
- 9.5.1 Market Overview
- 9.5.2 North America
- 9.5.3 Europe
- 9.5.4 Asia Pacific
- 9.5.5 Latin America
- 9.5.6 Middle East and Africa
- 10 North America Cardiometabolic Disease
- 10.1 Market Share by Country
- 10.2 United States of America
- 10.3 Canada
- 11 Europe Cardiometabolic Disease
- 11.1 Market Share by Country
- 11.2 United Kingdom
- 11.3 Germany
- 11.4 France
- 11.5 Italy
- 11.6 Others
- 12 Asia Pacific Cardiometabolic Disease
- 12.1 Market Share by Country
- 12.2 China
- 12.3 Japan
- 12.4 India
- 12.5 ASEAN
- 12.6 Australia
- 12.7 Others
- 13 Latin America Cardiometabolic Disease
- 13.1 Market Share by Country
- 13.2 Brazil
- 13.3 Argentina
- 13.4 Mexico
- 13.5 Others
- 14 Middle East and Africa Cardiometabolic Disease
- 14.1 Market Share by Country
- 14.2 Saudi Arabia
- 14.3 United Arab Emirates
- 14.4 Nigeria
- 14.5 South Africa
- 14.6 Others
- 15 Regulatory Framework
- 15.1 Regulatory Overview
- 15.1.1 US FDA
- 15.1.2 EU EMA
- 15.1.3 INDIA CDSCO
- 15.1.4 JAPAN PMDA
- 15.1.5 Others
- 16 Patent Analysis
- 16.1 Analysis by Type of Patent
- 16.2 Analysis by Publication year
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Patent Age
- 16.5 Analysis by CPC Analysis
- 16.6 Analysis by Patent Valuation
- 16.7 Analysis by Key Players
- 17 Grants Analysis
- 17.1 Analysis by year
- 17.2 Analysis by Amount Awarded
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Grant Application
- 17.5 Analysis by Funding Institute
- 17.6 Analysis by NIH Departments
- 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
- 18.1 Analysis by Trial Registration Year
- 18.2 Analysis by Trial Status
- 18.3 Analysis by Trial Phase
- 18.4 Analysis by Therapeutic Area
- 18.5 Analysis by Geography
- 19 Funding and Investment Analysis
- 19.1 Analysis by Funding Instances
- 19.2 Analysis by Type of Funding
- 19.3 Analysis by Funding Amount
- 19.4 Analysis by Leading Players
- 19.5 Analysis by Leading Investors
- 19.6 Analysis by Geography
- 20 Partnership and Collaborations Analysis
- 20.1 Analysis by Partnership Instances
- 20.2 Analysis by Type of Partnership
- 20.3 Analysis by Leading Players
- 20.4 Analysis by Geography
- 21 Supplier Landscape
- 21.1 biocrates life sciences ag
- 21.1.1 Financial Analysis
- 21.1.2 Product Portfolio
- 21.1.3 Demographic Reach and Achievements
- 21.1.4 Mergers and Acquisitions
- 21.1.5 Certifications
- 21.2 Lilly
- 21.2.1 Financial Analysis
- 21.2.2 Product Portfolio
- 21.2.3 Demographic Reach and Achievements
- 21.2.4 Mergers and Acquisitions
- 21.2.5 Certifications
- 21.3 Alnylam Pharmaceuticals, Inc.
- 21.3.1 Financial Analysis
- 21.3.2 Product Portfolio
- 21.3.3 Demographic Reach and Achievements
- 21.3.4 Mergers and Acquisitions
- 21.3.5 Certifications
- 21.4 Arrowhead Pharmaceuticals, Inc.
- 21.4.1 Financial Analysis
- 21.4.2 Product Portfolio
- 21.4.3 Demographic Reach and Achievements
- 21.4.4 Mergers and Acquisitions
- 21.4.5 Certifications
- 21.5 Dicerna Pharmaceuticals, Inc.
- 21.5.1 Financial Analysis
- 21.5.2 Product Portfolio
- 21.5.3 Demographic Reach and Achievements
- 21.5.4 Mergers and Acquisitions
- 21.5.5 Certifications
- 21.6 Cardax, Inc.
- 21.6.1 Financial Analysis
- 21.6.2 Product Portfolio
- 21.6.3 Demographic Reach and Achievements
- 21.6.4 Mergers and Acquisitions
- 21.6.5 Certifications
- 21.7 Novartis AG
- 21.7.1 Financial Analysis
- 21.7.2 Product Portfolio
- 21.7.3 Demographic Reach and Achievements
- 21.7.4 Mergers and Acquisitions
- 21.7.5 Certifications
- 21.8 Novo Nordisk A/S
- 21.8.1 Financial Analysis
- 21.8.2 Product Portfolio
- 21.8.3 Demographic Reach and Achievements
- 21.8.4 Mergers and Acquisitions
- 21.8.5 Certifications
- 21.9 Boehringer Ingelheim International GmbH
- 21.9.1 Financial Analysis
- 21.9.2 Product Portfolio
- 21.9.3 Demographic Reach and Achievements
- 21.9.4 Mergers and Acquisitions
- 21.9.5 Certifications
- 21.10 Kowa Company, Ltd
- 21.10.1 Financial Analysis
- 21.10.2 Product Portfolio
- 21.10.3 Demographic Reach and Achievements
- 21.10.4 Mergers and Acquisitions
- 21.10.5 Certifications
- 21.11 Allergan
- 21.11.1 Financial Analysis
- 21.11.2 Product Portfolio
- 21.11.3 Demographic Reach and Achievements
- 21.11.4 Mergers and Acquisitions
- 21.11.5 Certifications
- 21.12 AstraZeneca
- 21.12.1 Financial Analysis
- 21.12.2 Product Portfolio
- 21.12.3 Demographic Reach and Achievements
- 21.12.4 Mergers and Acquisitions
- 21.12.5 Certifications
- 22 Cardiometabolic Disease - Distribution Model (Additional Insight)
- 22.1 Overview
- 22.2 Potential Distributors
- 22.3 Key Parameters for Distribution Partner Assessment
- 23 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24 Company Competitiveness Analysis (Additional Insight)
- 24.1 Very Small Companies
- 24.2 Small Companies
- 24.3 Mid-Sized Companies
- 24.4 Large Companies
- 24.5 Very Large Companies
- 25 Payment Methods (Additional Insight)
- 25.1 Government Funded
- 25.2 Private Insurance
- 25.3 Out-of-Pocket
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook